Par Drugs & Che.

Why is Par Drugs & Chemicals Ltd falling/rising?

As of 10-Aug, Par Drugs & Chemicals Ltd's stock price is rising to 103.53, driven by a 43.7% increase in quarterly profit and record net sales of Rs 31.28 crore. The company's strong financial health and positive market sentiment further support this upward trend.

As of 10-Aug, Par Drugs & Chemicals Ltd's stock price is rising, currently at 103.53, reflecting a change of 5.13 (5.21%) upward. This increase can be attributed to several positive factors highlighted in the recent performance data. The company has reported significant growth in its quarterly profit after tax (PAT), which rose by 43.7% compared to the previous four-quarter average, reaching Rs 4.71 crore. Additionally, the net sales for the quarter were the highest recorded at Rs 31.28 crore, and the profit before depreciation, interest, and taxes (PBDIT) also reached a peak of Rs 6.38 crore.<BR><BR>The stock has outperformed the sector by 5.31% today, indicating strong market interest. Furthermore, it is trading above its moving averages across various time frames, which suggests a positive trend in its price movement. Despite a slight decline in investor participation, as evidenced by a decrease in delivery volume, the overall financial health of the company remains robust, being net-debt free and having an attractive valuation with a return on equity (ROE) of 12.9 and a price-to-book value of 1.1.<BR><BR>Overall, the combination of strong financial performance, positive market sentiment, and favorable trading conditions contributes to the rising stock price of Par Drugs & Chemicals Ltd.

Which are the latest news on Par Drugs & Che.?

Should I buy, sell or hold Par Drugs & Chemicals Ltd?

What does Par Drugs & Che. do?

Par Drugs & Chemicals Ltd is a Micro Cap company in the Chemicals & Petrochemicals industry, reporting net sales of 20 Cr and a profit of 1 Cr for the quarter ending March 2026. It has a market cap of INR 105 Cr, a P/E ratio of 8.00, and a return on equity of 11.71%.

Overview:<BR>Par Drugs & Chemicals Ltd operates in the Chemicals & Petrochemicals industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>The company was originally incorporated in 1999 as a Private Limited Company and later converted to a Public Limited Company in 2018. The latest quarterly results reported net sales and profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 20 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 1 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 105 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 8.00 <BR>Industry P/E: 42 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.37 <BR>Return on Equity: 11.71% <BR>Price to Book: 0.94 <BR><BR>Contact Details:<BR>Details: No Company Details Available <BR>Registrar Address: Not available.

How big is Par Drugs & Che.?

As of 10th June, Par Drugs & Chemicals Ltd has a market capitalization of 105.00 Cr, with recent net sales of 103.66 Cr and a net profit of 13.11 Cr over the latest four quarters.

As of 10th June, <BR><BR>Market Cap: Par Drugs & Chemicals Ltd has a market capitalization of 105.00 Cr, classifying it as a Micro Cap.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 103.66 Cr, while the sum of Net Profit for the same period is 13.11 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the balance sheet is March 2025. Shareholder's Funds are valued at 98.97 Cr, and Total Assets amount to 119.39 Cr.

Who are in the management team of Par Drugs & Che.?

The management team of Par Drugs & Che includes Falgun Vallabhbhai Savani (Chairman & Managing Director), Jigneshbhai Vallabhbhai Savani (Executive Director & CEO), and several other directors, including independent non-executive members. They are responsible for the company's governance and strategic direction.

The management team of Par Drugs & Che includes the following key members:<BR><BR>1. **Falgun Vallabhbhai Savani** - Chairman & Managing Director<BR>2. **Jigneshbhai Vallabhbhai Savani** - Executive Director & CEO<BR>3. **Ghanshayambhai Bhagvanbhai Savani** - Whole-Time Director & Executive Director<BR>4. **Nayna Jignesh Savani** - Non-Executive Director<BR>5. **Krishna Mitulbhai Shah** - Independent Non-Executive Director<BR>6. **Kajal Chintanbhai Vaghani** - Independent Non-Executive Director<BR>7. **Pravin Manjibhai Bhayani** - Independent Non-Executive Director<BR>8. **Bintal Bhaveshkumar Shah** - Independent Non-Executive Director<BR><BR>This team plays a crucial role in the governance and strategic direction of the company.

Who are the peers of the Par Drugs & Che.?

Par Drugs & Che. peers include Arvee Laboratories, Indian Phosphate, Vital Chemtech, Jocil, Hindcon Chemical, Paragon Fine, Indian Emuls, Sanginita Chemicals, and Unilex Colour & Chemicals. Par Drugs & Che. has average management and growth risks, with a 1-year return of -13.95%.

Peers: The peers of Par Drugs & Che. are Arvee Laborat., Indian Phosphate, Vital Chemtech, Jocil, Hindcon Chemical, Paragon Fine, Indian Emuls, Sanginita Chemi., and Unilex Colour &C.<BR><BR>Quality Snapshot: Excellent management risk is observed at Paragon Fine, while Average management risk is found at Indian Phosphate, Jocil, Hindcon Chemical, Par Drugs & Che., and Indian Emuls. Below Average management risk is noted at Arvee Laborat., Vital Chemtech, Sanginita Chemi., Unilex Colour &C, and Vadivarhe Speci. Growth is Excellent at Indian Emuls, while Average growth is found at Indian Phosphate, Jocil, Hindcon Chemical, Par Drugs & Che., and Paragon Fine. Below Average growth is observed at Arvee Laborat., Vital Chemtech, Sanginita Chemi., Unilex Colour &C, and Vadivarhe Speci. Capital Structure is Excellent at Indian Phosphate, Par Drugs & Che., and Paragon Fine, Good at Hindcon Chemical and Unilex Colour &C, and Below Average at Arvee Laborat., Vital Chemtech, Jocil, Sanginita Chemi., Indian Emuls, and Vadivarhe Speci.<BR><BR>Return Snapshot: Sanginita Chemi. has the highest 1-year return at 217.14%, while Indian Emuls has the lowest at -73.32%. Par Drugs & Che.'s 1-year return of -13.95% is better than Indian Emuls but worse than Sanginita Chemi. Additionally, several peers, including Hindcon Chemical, Indian Emuls, Unilex Colour &C, and Paragon Fine, have negative six-month returns.

Are Par Drugs & Chemicals Ltd latest results good or bad?

Par Drugs & Chemicals Ltd's latest results are concerning, with net sales dropping 33.16% to ₹19.61 crores and net profit falling 82.29% to ₹0.85 crores, indicating significant operational challenges and a decline in profitability. Investors should be cautious given these negative trends.

The latest results for Par Drugs & Chemicals Ltd indicate a significant downturn in performance, marking a challenging quarter for the company. In the March 2026 quarter, net sales dropped by 33.16% sequentially to ₹19.61 crores, which is the lowest quarterly sales figure in recent times. Additionally, net profit plummeted by 82.29% to just ₹0.85 crores, reflecting a sharp decline in profitability.<BR><BR>Operating margins also suffered, collapsing to 7.34% from 20.65% in the previous quarter, highlighting severe operational challenges. This deterioration stands in stark contrast to the company's strong nine-month performance, where net profit had surged by 153.36% earlier in the fiscal year.<BR><BR>Overall, the results are concerning, with multiple indicators pointing to operational difficulties and a decline in both revenue and profitability. Investors should be cautious as these trends raise questions about the company's ability to sustain its previous performance levels.

Is Par Drugs & Che. overvalued or undervalued?

As of November 17, 2025, Par Drugs & Chemicals is fairly valued with a PE ratio of 11.95 and an EV to EBIT of 8.99, significantly lower than its expensive peers, but has underperformed the Sensex with a stock return of -65.29%.

As of 17 November 2025, the valuation grade for Par Drugs & Chemicals has moved from very attractive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 11.95, an EV to EBIT of 8.99, and an ROCE of 22.22%. <BR><BR>In comparison to its peers, Par Drugs & Chemicals has a PE ratio significantly lower than Solar Industries at 95.31 and Gujarat Fluoroch at 57.85, both of which are deemed very expensive. Additionally, the company’s EV to EBITDA of 6.54 is more favorable than that of Godrej Industries, which stands at 40.96, classified as attractive. Notably, Par Drugs & Chemicals has underperformed the Sensex significantly over the past year, with a stock return of -65.29% compared to the Sensex's 10.54%, reinforcing the notion that the stock may be fairly valued at present.

How has been the historical performance of Par Drugs & Che.?

Par Drugs & Che. has shown consistent growth in net sales and profits, with net sales increasing from 55.85 Cr in Mar'20 to 100.97 Cr in Mar'25, and profit after tax reaching 13.36 Cr in Mar'25. Despite rising costs and cash flow challenges, the company maintains a healthy profit margin of 13.23%.

Answer:<BR>The historical performance of Par Drugs & Che. shows a consistent growth trend in net sales and profits over the years, with some fluctuations in specific metrics.<BR><BR>Breakdown:<BR>Par Drugs & Che. has demonstrated a steady increase in net sales, rising from 55.85 Cr in Mar'20 to 100.97 Cr in Mar'25. Total operating income has followed a similar trajectory, reaching 100.97 Cr in Mar'25, up from 46.32 Cr in Mar'19. The company's total expenditure, excluding depreciation, increased to 81.47 Cr in Mar'25 from 38.12 Cr in Mar'19, reflecting rising costs, particularly in raw materials, which amounted to 39.41 Cr in Mar'25. Operating profit (PBDIT) has shown variability, peaking at 23.06 Cr in Mar'24 before declining to 21.65 Cr in Mar'25. Profit before tax reached 17.92 Cr in Mar'25, while profit after tax was 13.36 Cr, indicating a healthy profit margin of 13.23%. The company's total assets grew significantly to 119.39 Cr in Mar'25 from 60.12 Cr in Mar'20, with total liabilities also increasing to 119.39 Cr in Mar'25. Cash flow from operating activities was 16.00 Cr in Mar'25, although the net cash outflow was -9.00 Cr, down from a net inflow of 14.00 Cr in Mar'24. Overall, Par Drugs & Che. has shown robust growth in sales and profitability, despite some challenges in cash flow management.

What is the technical trend for Par Drugs & Che.?

As of May 12, 2025, Par Drugs & Che exhibits a mildly bearish trend overall, with mixed signals from key indicators such as a mildly bullish weekly MACD and bearish daily moving averages.

As of 12 May 2025, the technical trend for Par Drugs & Che has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD remains bearish. The RSI shows no signal on the weekly chart but is bullish on the monthly. Bollinger Bands are bearish on both weekly and monthly time frames. Daily moving averages are bearish, and the KST is mildly bullish weekly but bearish monthly. Dow Theory shows a mildly bullish trend on the weekly chart with no trend on the monthly. The OBV is mildly bearish weekly and mildly bullish monthly. Overall, the current stance is mildly bearish, with key indicators such as the daily moving averages and Bollinger Bands contributing to this view.

Who are the top shareholders of the Par Drugs & Che.?

The top shareholder of Par Drugs & Che. is Jignesh Vallabhbhai Savani, holding 21.88%. Other significant shareholders include Econo Trading And Investment Private Limited at 1.78% and individual investors with a combined stake of 20.3%.

The top shareholders of Par Drugs & Che. include the promoters, with Jignesh Vallabhbhai Savani holding the highest stake at 21.88%. There are no pledged promoter holdings, and the company is also held by two foreign institutional investors, although their combined stake is negligible at 0.0%. The highest public shareholder is Econo Trading And Investment Private Limited, which holds 1.78%. Additionally, individual investors collectively hold 20.3% of the company.

When is the next results date for Par Drugs & Che.?

No Upcoming Board Meetings

What is the bonus history of the Par Drugs & Che.?

Par Drugs & Chemicals Ltd issued a 1:1 bonus on April 27, 2021, with a record date of April 28, 2021, granting shareholders an additional share for each share held.

Par Drugs & Chemicals Ltd has a bonus history that includes a 1:1 bonus issue announced with an ex-date of April 27, 2021. The record date for this bonus was April 28, 2021. This means that shareholders on record as of that date received an additional share for every share they held.

Has Par Drugs & Che. declared dividend?

Par Drugs & Chemicals Ltd has declared a 12% dividend, amounting to 1.2 per share, with an ex-date of November 22, 2021. Despite the dividend declaration, the dividend yield is 0%, and the company has experienced significant volatility in total returns, ranging from -57.37% over 6 months to 495.27% over 5 years.

Par Drugs & Chemicals Ltd has declared a 12% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 12%<BR>- Amount per share: 1.2<BR>- Ex-date: 22 Nov 21<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -57.37%, the dividend return was 0%, resulting in a total return of -57.37%.<BR><BR>In the 1-year period, the price return was -55.99%, the dividend return was 0%, resulting in a total return of -55.99%.<BR><BR>In the 2-year period, the price return was -52.72%, the dividend return was 0%, resulting in a total return of -52.72%.<BR><BR>In the 3-year period, the price return was -32.61%, the dividend return was 0%, resulting in a total return of -32.61%.<BR><BR>In the 4-year period, the price return was 51.47%, the dividend return was 1.31%, resulting in a total return of 52.78%.<BR><BR>In the 5-year period, the price return was 490.29%, the dividend return was 4.98%, resulting in a total return of 495.27%.<BR><BR>Overall, while Par Drugs & Chemicals Ltd has declared a dividend, the dividend yield remains at 0%. The total returns over various periods show significant volatility, with negative returns in the shorter terms and substantial positive returns over the longer term, particularly in the 5-year period.